Phio Pharmaceuticals Corp. reported its financial results for the third quarter of 2025, revealing a net loss of $2.4 million, compared to a net loss of $1.5 million for the same period in 2024. The company's operating expenses increased to $2.5 million from $1.6 million year-over-year, driven primarily by higher research and development costs associated with its lead product candidate, PH-762. For the nine months ended September 30, 2025, the net loss was $6.3 million, up from $5.5 million in the prior year, reflecting a continued investment in clinical trials and operational activities.

The company's total assets as of September 30, 2025, stood at $11.5 million, a significant increase from $5.7 million at the end of 2024. This growth was largely attributed to a rise in cash and cash equivalents, which reached $10.7 million, compared to $5.4 million at the end of the previous fiscal year. The increase in cash reserves was bolstered by financing activities, including the exercise of warrants and the issuance of common stock, which collectively provided $11.2 million in net cash for the nine months ended September 30, 2025, compared to $2.6 million in the same period of 2024.

Operationally, Phio Pharmaceuticals has made strategic adjustments, including a shift to remote operations and a reduction in workforce by over 50% to streamline costs. The company is focused on advancing its clinical trial for PH-762, which is currently in a Phase 1b trial targeting various skin cancers. The trial has shown promising results, with significant tumor clearance observed in several patients. Additionally, the company terminated its collaboration agreement with AgonOx in May 2024, which has allowed it to redirect resources towards its own clinical programs without incurring further financial obligations to AgonOx.

Looking ahead, Phio Pharmaceuticals anticipates that its current cash position, bolstered by recent financing efforts, will be sufficient to meet its operational needs for at least the next 12 months. However, the company acknowledges the ongoing challenges of securing additional funding and the inherent risks associated with clinical development. The management remains committed to advancing its product candidates and is actively evaluating opportunities for future financing to support its growth and operational objectives.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals is a clinical-stage biotech company developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference technology. Its focus is on creating targeted cancer treatments that enhance immune cell effectiveness without complex delivery systems. The company’s pipeline includes gene-silencing compounds like PH-762, targeting proteins such as PD-1, aimed at treating various cancers through intratumoral injections and adoptive cell therapy.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.